From: First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses
Inactivation method
Log10 reduction
Master virus bank (Log10TCID50/ml)
Putative safety margin
AT-2
≥4.83 ± 0.26
5.64 ± 0.10
≥4.71 log units
Gamma irradiation
≥5.52 ± 0.33